Veeco Instruments entered into a senior secured revolving credit facility. The Facility enables the company to borrow up to $150 million over a 5-year term which expires in December of 2026. HSBC Bank USA is acting as administrative agent and collateral agent. HSBC Bank along with, Barclays Bank PLC, Santander Bank, and Citibank served as joint lead arranger and joint bookrunner on the Facility with Silicon Valley Bank as an additional lender.“We are pleased to secure a $150 million facility at
Read Story
December 17, 2021 @ 07:50 AM
|
According to a Bloomberg report, Bank of Montreal has expressed interest in buying BNP Paribas SA’s U.S. banking arm, according to people familiar with the matter. BMO has held initial talks about an acquisition of BNP Paribas’s Bank of the West unit. Reuters last month reported BNP Paribas was working with advisers to assess a sale Bank of the West.Read the Bloomberg article here.
Read Story
December 17, 2021 @ 08:03 AM
|
BMO Financial Group, and its indirect wholly owned Chicago-based subsidiary BMO Harris Bank announced the signing of a definitive agreement with BNP Paribas to acquire Bank of the West and its subsidiaries, with assets as of Sept. 30, 2021, of approximately $105 billion. This acquisition aligns with BMO's strategic, financial and cultural objectives.Under the terms of the agreement, BMO will acquire Bank of the West for a cash purchase price of $16.3 billion, or $13.4 billion net of estimated $2
Read Story
December 20, 2021 @ 08:05 AM
|
A-Mark Precious Metals, a leading fully integrated precious metals platform, closed a new three-year, committed $350 million credit facility led by CIBC Bank USA, replacing its existing $280 million credit facility. The new credit facility became effective on December 21, 2021 and matures on December 20, 2024. CIBC Bank USA acted as Administrative Agent, and Joint Lead Arranger.“The new credit facility reflects the strong performance of our business and our capital partners’ confidence in the
Read Story
December 22, 2021 @ 07:33 AM
|
Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, obtained a $225 million term loan facility from funds managed by SLR Capital Partners (“SLR”). This additional capital further strengthens Arcutis’ balance sheet in advance of a potential 2022 Food and Drug Administration (FDA) approval and launch of topical roflumilast cream in plaque psoriasis, and in advance of three 2022 pivotal clinical data readouts in atopic
Read Story
December 27, 2021 @ 08:03 AM
|